Clinical trial · Observational
Invasives Aspergillosis in Acute Myeloid Leukemia
The Incidence of Invasive Aspergillosis in Acute Myeloid Leukemia
NCT02900430CI-TRIAL-00023874IA-AMLcompletedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with acute myeloid leukemia (AML) are at risk to develop severe infections whose invasive aspergillosis (IA). These infections are leading to an important morbidity and mortality. Antifungal prophylaxis is recommended by posaconazole for AML patients during neutropenia induced by induction chemotherapy. Their application is not uniform.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Acute Myeloid Leukemia | Acute Myeloid Leukemia | CURATED_BROADER | 0.80 |
| Invasive Aspergillosis | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Patients with antifungal prophylaxis | Drug | — | UNRESOLVED |
| Patients without antifungal prophylaxis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Patients without antifungal prophylaxis
- description
- Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2009 to 2011, any patient received antifungal (anti-aspergillosis) prophylaxis.
- interventionNames
- Other: Patients without antifungal prophylaxis
- label
- Patients with antifungal prophylaxis
- description
- Patients with acute myeloid leukemia treated with intensive chemotherapy. From 2012 to 2015, all patients received antifungal (anti-aspergillosis) prophylaxis by posaconazole.
- interventionNames
- Other: Patients without antifungal prophylaxis
- Drug: Patients with antifungal prophylaxis
Primary outcomes (1)
- measure
- Incidence of invasive aspergillosis in acute myeloid leukemia
- timeFrame
- 1 year
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * \> 18 years * acute myeloid leukemia * intensive chemotherapy (induction, consolidation, salvage, bone marrow transplantation) Exclusion Criteria: * \< 18 years * pregnancy * no intensive chemotherapy (palliative treatment, azacytidine...)
References
Publications (0)
Data not yet available
No reference posted for this study.